Open Access

HLA DRB1*03 as a possible common etiology of schizophrenia, Graves’ disease, and type 2 diabetes

  • Aicha Sayeh1, 2,
  • Cheker Ben Cheikh3, 4,
  • Ali Mardessi4, 5,
  • Meriem Mrad1, 2,
  • Brahim Nsiri1,
  • Abdelaziz Oumaya3, 4 and
  • Najiba Fekih-Mrissa1, 6Email author
Annals of General Psychiatry201716:7

https://doi.org/10.1186/s12991-017-0128-4

Received: 22 September 2016

Accepted: 12 January 2017

Published: 2 February 2017

Abstract

Background

Autoimmune diseases and schizophrenia share many common features. Association studies confirm a shared genetic association in the human leukocyte antigen (HLA) region between schizophrenia and most autoimmune diseases. To our knowledge, the simultaneous syndromes of Graves’ disease (GD) and type 2 diabetes (T2D) in schizophrenia are rare in Tunisia.

Case presentation

We report a case of a 42-year-old woman admitted to the department of psychiatry for an acute relapse of chronic schizophrenia. Her medical history revealed that she was followed for Graves’ disease and for a type 2 diabetes mellitus. A low-resolution HLA typing was performed by polymerase chain reaction sequence-specific primer (PCR-SSP) techniques according to determine the patient’s haplotype.

Conclusions

Our study suggests that the HLA DRB1*03 allele may explain a common etiology underlying the co-morbidity of Graves’ disease, type 2 diabetes, and schizophrenia in our patient.

Keywords

Graves’ disease Schizophrenia Type 2 diabetes HLA Autoimmunity

Background

People with schizophrenia often develop somatic symptoms, particularly autoimmune disorders [1]. Previous studies have reported that, compared with the general population, individuals with schizophrenia have a different prevalence of some autoimmune diseases and experience different immunological responses [1, 2]. Autoimmune involvement may have potential influence on central nervous system (CNS) pathologies which generates antibodies against the brain tissue in those with schizophrenia [3, 4]. A pathogenic theory of schizophrenia posits its proximate cause to be an infection during early development whereby antigens, similar to that found in CNS tissue, give rise to auto-antibodies that act against the brain.

Dopamine, which is inhibitory to TSH secretion, was found to be increased in schizophrenic patients. Subsequent clinical evidence has also shown an excess of thyroid hormone dysfunction in schizophrenia that can result in cognitive function impairment with emotional and behavioral disturbances. Furthermore, other studies have revealed an association between Graves’ disease and schizophrenia. Some have attributed these manifold observations to dysfunction of the hypothalamus-pituitary-thyroid axis [57].

Case presentation

A 42-year-old woman was admitted to the Department of Psychiatry of the Military Hospital of Tunis for an acute relapse of chronic schizophrenia. Her medical history revealed that the patient was followed for seven years for Graves’ disease treated by synthetic anti-thyroids and for a type 2 diabetes mellitus treated by metformin. The patient received antipsychotic therapy for three weeks during recovery in the Department of Psychiatry and is now followed regularly for her associated diseases. The co-existence of those diseases has motivated a genetic analysis to seek a common syndromic pathology. The patient gave informed consent to giving a blood sample for genetic analysis. The study protocol was approved by the Ethics Committee of the Military Hospital of Tunisia and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

HLA typing by DNA amplification

Genomic DNA was extracted from peripheral blood samples of patients and healthy individuals using the QIAamp DNA Blood Mini Kit (QIAGEN GmbH, Hilden, Germany). Low-resolution HLA typing was performed by polymerase chain reaction sequence-specific primer (PCR-SSP) techniques according to Micro SSP DNA Typing Trays DRB/DQB (One Lambda Inc. Canoga Park, California, USA). Amplified DNA fragments were detected by agarose gel electrophoresis (2.5% agarose gel), stained with ethidium bromide, and UV transillumination. One Lambda DNA/LMT software version 3.98 was used to detect specific DRB1 and DQB1 alleles.

Results

The genetic investigation revealed that the patient carried the HLA DRB1*03-HLA DQB1*02 haplotype. We suppose that HLA DRB1*03 may be the common cause of these three simultaneous diseases.

Discussion

We report a case of a patient presenting co-occurrences of Graves’ disease, type 2 diabetes, and schizophrenia. The genetic investigation revealed that the patient carried the DRB1*03-DQB1*02 haplotype. Many subsequent studies have noted similarities between schizophrenia and other autoimmune diseases [1]. Firstly, the diagnostic procedures are largely dependent on clinical criteria such as the lack of a specific etiological diagnosis. Secondly, the treatments are usually palliative, not curative. Thirdly, both are complex disorders caused by multiple genetic, environmental, and lifestyle factors, and the interaction between these factors do not follow a clear Mendelian pattern of inheritance. Furthermore, due to limited knowledge of pathophysiology, individuals with schizophrenia and/or certain autoimmune diseases may be similar in clinical presentation, but their underlying etiologies are very heterogeneous.

Recent genome-wide association studies have identified a growing number of disease-associated loci and have provided enormous insight into the etiology of complex genetic disorders, including schizophrenia and autoimmune diseases [8, 9].

Strikingly, consistent with the results from previous linkage and case–control association studies, genome-wide association study results confirmed a shared genetic association in the human leukocyte antigen (HLA) region between schizophrenia and most autoimmune diseases. Caucasian patients with GD usually present the HLA-DRB1*03 allele in strong linkage disequilibrium with the HLA-DQB1*0201 [10, 11]. Also, in native South Africans, HLA-DR1 has been associated with GD [12]. Moreover, very few studies examined a possible role for HLA class II in type 2 diabetes in relation to autoimmune markers and latent autoimmune diabetes in adults and association with complications of diabetes. This was exemplified by the findings that DQB1*0201 and DQB1*0302 [13], DRB1*03/04-DQB1*0302 [14, 15], and DRB1*03-DQA1*0502-DQB1*0201 (DR3-DQ2) were positively associated with type 2 diabetes [16]. Furthermore, the HLA-DRB1 gene has been a focus in investigating the HLA association with schizophrenia [17]. A strong positive association between HLA-DRB1*03 and HLA DQB1*02 alleles and schizophrenia has widely been reported in the Saudi and Tunisian populations [18, 19].

Although associations between the HLA loci and GD, schizophrenia, and T2D are well established, the underlying mechanisms through which HLA molecules confer susceptibility to those diseases simultaneously are still unclear. It is known that the major function of HLA class II molecules (DR, DQ, and DP), in the normal cellular and humoral immune response, is to bind peptide antigens and present them to T cell receptors [20]. There is persuasive evidence that these diseases are associated with specific amino acid sequences of the DRB1 and DQ genes. It is thought that different HLA alleles have different affinities for peptides from auto-antigens such as the TSH receptor, dopamine receptors, and GAD antibodies. Knight postulates that the acute positive symptoms of schizophrenia are caused by auto-antibodies which interact with and stimulate dopamine receptors in certain neural pathways of the brain (dopamine-receptor-stimulating auto-antibodies) [21]. Despite the failure of some studies to detect dopamine receptor auto-antibodies in schizophrenia patients [22, 23], the hypothesis of a major role of dopamine receptor serum antibodies is further supported by recent findings of an increased production of pro-inflammatory cytokines and auto-antibodies in acutely ill schizophrenia patients [24, 25]. These antibodies would be analogous to the thyroid-stimulating auto-antibodies which cause the hyperthyroidism of Graves’ disease [21]. In the same way, GAD antibodies would also be analogous to both previously discussed antibodies. Thus, only specific HLA-DR alleles with the appropriate amino acids in its peptide-binding pocket would allow an auto-antigenic peptide to bind and to be recognized by the T-cell receptor [26]. This will eventually lead to hyperthyroidism by overproduction of thyroid-stimulating auto-antibodies. Specifically, HLA-DRB1 may predispose to an autoimmune-mediated reduction in insulin secretory function, either by a loss of beta cell mass or interference with early insulin release [27, 28]. Although not all schizophrenic patients suffer from glucose dysfunction, recent evidence has indicated a propensity toward such an association. Schoepf et al. [29] demonstrated that the prevalence of type 2 diabetes was increased in schizophrenia compared to hospitalized controls, while the findings of Perry et al. [30] suggests a potential link between pre-diabetic markers, in particular impaired glucose tolerance and insulin resistance, and first-episode psychosis.

Very few studies, to date, have examined the correlation between the structure of the HLA-DRB1 polymorphism and GD, schizophrenia, and T2D. A few studies have shown that an arginine residue at position 74 of the HLA-DRB1 chain plays an important role in the genetic susceptibility to those diseases [31, 32]. Since most DR3 subtypes contain DRb-Arg74 it was possible that the association of DRb-Arg74 with GD was merely a reflection of the association of DR3 with GD, schizophrenia, and T2D [31]. It is much more likely that the DR structure itself could explain some of the well-established DR3 associations with these autoimmune diseases.

Conclusion

Our study suggests that the HLA DRB1*03 haplotype may explain a common etiology underlying the co-morbidity of Graves’ disease, type 2 diabetes, and schizophrenia.

Abbreviations

GD: 

Graves’ disease

DT2: 

type 2 diabetes

HLA: 

human leukocyte antigen

Declarations

Authors’ contributions

AS was critically involved in the collection of the data, contributed intellectually to the interpretation of the data, wrote the first draft of the manuscript, and contributed to the editing of the final manuscript. CBC, AM, MM, BN, and AO were heavily involved in the collection of data and contributed intellectually to the interpretation of data. All authors read and approved the final manuscript. NFM supervised the entire project and was critically involved in the design and interpretation of the data. All authors read and approved the final manuscript.

Acknowledgements

We would like to thank Dr. Christian Winchell for his precious help in correcting this manuscript.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

All data generated during this study are included in this published article.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Ethics approval and consent to participate

The participant gave informed consent to giving a blood sample for genetic analysis. The study protocol was approved by the ethics committee of the Military Hospital of Tunis and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Laboratoire de Biologie Moléculaire, Service d’Hématologie., Hôpital Militaire de Tunis
(2)
Faculté des Sciences de Tunis, Université Tunis el Manar
(3)
Service de Psychiatrie, Hôpital Militaire de Tunis
(4)
Faculté de Médecine de Tunis, Université de Tunis El Manar
(5)
Service Oto-rhino-laryngologie, Hôpital Militaire de Tunis
(6)
Académie Militaire Fondouk Jédid

References

  1. Jones AL, Mowry BJ, Pender MP, Greer JM. Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis? Immunol Cell Biol. 2005;83:9–17.View ArticlePubMedGoogle Scholar
  2. Strous RD, Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun. 2006;27:71–80.View ArticlePubMedGoogle Scholar
  3. Irani SR, Gelfand JM, Diwani A, Vincent A. Cell-surface central nervous system autoantibodies: clinical relevance and emerging paradigms. Ann Neurol. 2014;76:168–84.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Vincent A, Bien CG, Irani SR, Waters P. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol. 2011;10:759–72.View ArticlePubMedGoogle Scholar
  5. Eaton WW, Byrne M, Ewald H, Mors O, Chen CY, Agerbo E, Mortensen PB. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry. 2006;163:521–8.View ArticlePubMedGoogle Scholar
  6. Othman SS, Kadir KA, Hassan J, Hong GK, Singh BB, Raman N. High prevalence of thyroid function test abnormalities in chronic schizophrenia. Aust NZ J Psychiatry. 1994;28:620–4.View ArticleGoogle Scholar
  7. Chen SJ, Chao YL, Chen CY, Chang CM, Wu ECH, Wu CH, et al. Prevalence of autoimmune diseases in in-patients with schizophrenia: nationwide population-based study. Br J Psychiatry. 2012;200:374–80.View ArticlePubMedGoogle Scholar
  8. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–7.View ArticlePubMed CentralGoogle Scholar
  9. Ramos PS, Shedlock AM, Langefeld CD. Genetics of autoimmune diseases: insights from population genetics. J Hum Genet. 2015;60:657–64.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Boehm BO, Kuhnl P, Manfras BJ, Chen M, Lee JC, Holzberger G, et al. HLA-DRB3 gene alleles in Caucasian patients with Graves’ disease. Clin Investig. 1992;70:956–60.View ArticlePubMedGoogle Scholar
  11. Chen QY, Huang W, She JX, Baxter F, Volpe R, Maclaren NK. HLA-DRB1*08, DRB1*03/DRB3*0101, and DRB3*0202 are susceptibility genes for Graves’ disease in North American Caucasians, whereas DRB1*07 is protective. J Clin Endocrinol Metab. 1999;84:3182–6.PubMedGoogle Scholar
  12. Omar MA, Hammond MG, Desai RK, Motala AA, Aboo N, Seedat MA. HLA class I and II antigens in South African blacks with Graves’ disease. Clin Immunol Immunopathol. 1990;54:98–102.View ArticlePubMedGoogle Scholar
  13. Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A, et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes. 1999;48:150–7.View ArticlePubMedGoogle Scholar
  14. Horton V, Stratton I, Bottazzo GF, Shattock M, Mackay I, Zimmet P, et al. Genetic heterogeneity of autoimmune diabetes: age of presentation in adults is influenced by HLA DRB1 and DQB genotypes (UKPDS 43). Diabetologia. 1999;42:608–16.View ArticlePubMedGoogle Scholar
  15. Richens ER, Abdella N, Jayyab AK, Al-Saffar M, Behbehani K. Type 2 diabetes in Arab patients in Kuwait. Diabet Med. 1988;5:231–4.View ArticlePubMedGoogle Scholar
  16. Gambelunghe G, Forini F, Laureti S, Murdolo G, Toraldo G, Santeusanio F, et al. Increased risk for endocrine autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibodies. Clin Endocrinol. 2000;52:565–73.View ArticleGoogle Scholar
  17. International Schizophrenia Consortium, Purcell SM, Wray NR, Stone JL, Visscher PM, O’Donovan MC, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460:748–52.PubMed CentralGoogle Scholar
  18. Kadasah S, Arfin M, Tariq M. HLA-DRB1 association with schizophrenia in Saudi Arabian patients. Int J Psychiatry Clin Pract. 2011;15:112–7.View ArticlePubMedGoogle Scholar
  19. Sayeh A, Cheikh CB, Mrad M, Lakhal N, Gritli N, Galelli S, et al. Association of HLA-DR/DQ polymorphisms with schizophrenia in Tunisian patients. Ann Saudi Med. 2014;34:503–7.PubMedGoogle Scholar
  20. McDevitt HO. The role of MHC class II molecules in susceptibility and resistance to autoimmunity. Curr Opin Immunol. 1998;10:677–81.View ArticlePubMedGoogle Scholar
  21. Knight JG. Dopamine-receptor-stimulating autoantibodies: a possible cause of schizophrenia. Lancet. 1982;2:1073–6.View ArticlePubMedGoogle Scholar
  22. von Kirchbach A, Fischer EG, Kornhuber HH. Failure to detect dopamine receptor IgG autoantibodies in sera of schizophrenic patients. Short note. J Neural Transm. 1987;70:175–9.View ArticleGoogle Scholar
  23. Müller UJ, Teegen B, Probst C, Bernstein HG, Busse S, Bogerts B, et al. Absence of dopamine receptor serum autoantibodies in schizophrenia patients with an acute disease episode. Schizophr Res. 2014;158:272–4.View ArticlePubMedGoogle Scholar
  24. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70:663–71.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Ezeoke A, Mellor A, Buckley P, Miller B. A systematic, quantitative, review of blood autoantibodies in schizophrenia. Schizophr Res. 2013;150:245–51.View ArticlePubMedGoogle Scholar
  26. Jacobson EM, Huber A, Tomer Y. The HLA gene complex in thyroid autoimmunity: from epidemiology to etiology. J Autoimmun. 2008;30:58–62.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Rodriguez-Venturaa AL, Yamamoto-Furushob JK, Coyotea N, Dorantesa LM, Ruiz-Moralesb JA, Vargas-Alarconc G, et al. HLA-DRB1*08 allele may help to distinguish between type 1 diabetes mellitus and type 2 diabetes mellitus in Mexican children. Pediatr Diabetes. 2007;8:5–10.View ArticleGoogle Scholar
  28. Williams RC, Muller YL, Hanson RL, Knowler WC, Mason CC, Bian L, et al. HLA-DRB1 reduces the risk of type 2 diabetes mellitus by increased insulin secretion. Diabetologia. 2011;54:1684–92.View ArticlePubMedGoogle Scholar
  29. Schoepf D, Potluri R, Uppal H, Natalwala A, Narendran P, Heun R. Type-2 diabetes mellitus in schizophrenia: increased prevalence and major risk factor of excess mortality in a naturalistic 7-year follow-up. Eur Psychiatry. 2012;27:33–42.View ArticlePubMedGoogle Scholar
  30. Perry BI, McIntosh G, Weich S, Singh S, Rees K. The association between first-episode psychosis and abnormal glycaemic control: systematic review and meta-analysis. Lancet Psychiatry. 2016;3:1049–58.View ArticlePubMedGoogle Scholar
  31. Ban Y, Davies TF, Greenberg DA, Concepcion ES, Osman R, Oashi T, et al. Arginine at position 74 of the HLA-DRb1 chain is associated with Graves’ disease. Genes Immun. 2004;5:203–8.View ArticlePubMedGoogle Scholar
  32. Simmonds MJ, Howson JM, Heward JM, Cordell HJ, Foxall H, Carr-Smith J, et al. Regression mapping of association between the human leukocyte antigen REGION and Graves disease. Am J Hum Genet. 2005;76:157–63.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s) 2017

Advertisement